Kiora Pharmaceuticals (KPRX) Competitors $2.54 -0.06 (-2.31%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.49 -0.05 (-1.97%) As of 08/1/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock KPRX vs. CLSD, DYAI, MDCX, SNYR, ESLA, IXHL, GBIO, KZR, ALXO, and ITRMShould you be buying Kiora Pharmaceuticals stock or one of its competitors? The main competitors of Kiora Pharmaceuticals include Clearside Biomedical (CLSD), Dyadic International (DYAI), Medicus Pharma (MDCX), Synergy CHC (SNYR), Estrella Immunopharma (ESLA), Incannex Healthcare (IXHL), Generation Bio (GBIO), Kezar Life Sciences (KZR), ALX Oncology (ALXO), and Iterum Therapeutics (ITRM). These companies are all part of the "pharmaceutical products" industry. Kiora Pharmaceuticals vs. Its Competitors Clearside Biomedical Dyadic International Medicus Pharma Synergy CHC Estrella Immunopharma Incannex Healthcare Generation Bio Kezar Life Sciences ALX Oncology Iterum Therapeutics Kiora Pharmaceuticals (NASDAQ:KPRX) and Clearside Biomedical (NASDAQ:CLSD) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends and institutional ownership. Do analysts recommend KPRX or CLSD? Kiora Pharmaceuticals currently has a consensus target price of $10.00, indicating a potential upside of 293.70%. Clearside Biomedical has a consensus target price of $4.20, indicating a potential upside of 993.47%. Given Clearside Biomedical's higher possible upside, analysts plainly believe Clearside Biomedical is more favorable than Kiora Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kiora Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Clearside Biomedical 0 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.17 Which has more volatility & risk, KPRX or CLSD? Kiora Pharmaceuticals has a beta of -0.66, suggesting that its stock price is 166% less volatile than the S&P 500. Comparatively, Clearside Biomedical has a beta of 2.09, suggesting that its stock price is 109% more volatile than the S&P 500. Is KPRX or CLSD more profitable? Kiora Pharmaceuticals has a net margin of 0.00% compared to Clearside Biomedical's net margin of -818.57%. Clearside Biomedical's return on equity of 0.00% beat Kiora Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Kiora PharmaceuticalsN/A -42.82% -32.18% Clearside Biomedical -818.57%N/A -114.23% Does the media prefer KPRX or CLSD? In the previous week, Kiora Pharmaceuticals' average media sentiment score of 0.00 equaled Clearside Biomedical'saverage media sentiment score. Company Overall Sentiment Kiora Pharmaceuticals Neutral Clearside Biomedical Neutral Which has better earnings and valuation, KPRX or CLSD? Kiora Pharmaceuticals has higher earnings, but lower revenue than Clearside Biomedical. Clearside Biomedical is trading at a lower price-to-earnings ratio than Kiora Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKiora PharmaceuticalsN/AN/A$3.60M-$2.90-0.88Clearside Biomedical$1.66M17.98-$34.35M-$0.41-0.94 Do insiders & institutionals have more ownership in KPRX or CLSD? 77.0% of Kiora Pharmaceuticals shares are held by institutional investors. Comparatively, 18.8% of Clearside Biomedical shares are held by institutional investors. 0.1% of Kiora Pharmaceuticals shares are held by insiders. Comparatively, 6.2% of Clearside Biomedical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. SummaryKiora Pharmaceuticals and Clearside Biomedical tied by winning 6 of the 12 factors compared between the two stocks. Get Kiora Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KPRX vs. The Competition Export to ExcelMetricKiora PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.91M$2.46B$5.49B$9.52BDividend YieldN/A1.81%4.73%4.09%P/E Ratio-0.888.9728.7823.81Price / SalesN/A437.65372.2066.04Price / Cash2.10157.7635.4557.96Price / Book0.304.838.275.54Net Income$3.60M$31.62M$3.25B$259.28M7 Day Performance-15.05%-5.28%-3.70%-4.64%1 Month Performance-11.19%4.38%4.34%4.41%1 Year Performance-42.40%-2.49%25.90%17.95% Kiora Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KPRXKiora Pharmaceuticals3.1183 of 5 stars$2.54-2.3%$10.00+293.7%-43.9%$7.91MN/A-0.8810Upcoming EarningsCLSDClearside Biomedical2.3953 of 5 stars$0.45+0.2%$4.20+841.7%-66.0%$34.66M$1.66M-1.0930Gap DownDYAIDyadic International2.0793 of 5 stars$1.14+2.3%$6.00+428.2%-25.6%$34.18M$3.49M-5.687News CoveragePositive NewsMDCXMedicus Pharma2.4642 of 5 stars$2.49+2.0%$23.50+843.8%N/A$33.80MN/A-2.15N/AUpcoming EarningsSNYRSynergy CHC3.875 of 5 stars$3.60-3.2%$10.00+177.8%+3,260.0%$33.08M$34.83M0.0040Trending NewsESLAEstrella Immunopharma2.9551 of 5 stars$0.91+0.4%$16.00+1,650.5%-51.2%$33.06MN/A-3.52N/AIXHLIncannex Healthcare0.5859 of 5 stars$1.12-6.1%N/A-80.0%$32.87M$10K-0.923News CoverageGap DownGBIOGeneration Bio3.7081 of 5 stars$4.84+3.0%$80.00+1,552.9%-86.7%$32.44M$24.56M-0.45150Upcoming EarningsGap DownKZRKezar Life Sciences3.6576 of 5 stars$4.44+1.7%$39.50+790.6%-36.1%$32.42M$7M-0.4160Negative NewsAnalyst DowngradeShort Interest ↑ALXOALX Oncology3.2601 of 5 stars$0.61-3.2%$3.30+444.6%-81.5%$32.36MN/A-0.2540Positive NewsGap DownITRMIterum Therapeutics1.5798 of 5 stars$0.81+3.2%$9.00+1,018.0%-37.7%$32.20MN/A-0.8110Upcoming EarningsShort Interest ↑Gap Up Related Companies and Tools Related Companies Clearside Biomedical Competitors Dyadic International Competitors Medicus Pharma Competitors Synergy CHC Competitors Estrella Immunopharma Competitors Incannex Healthcare Competitors Generation Bio Competitors Kezar Life Sciences Competitors ALX Oncology Competitors Iterum Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KPRX) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiora Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kiora Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
